Dr Ameer Hassan shares his excitement for 2026, highlighting the NeVa VS DILATE Registry and the growing global data on endovascular treatment for subarachnoid haemorrhage vasospasm, with encouraging results showing most patients don’t require retreatment.

Turning to ischaemic stroke, Dr Raul Nogueira discusses major advances in contact aspiration and emerging innovation on the stent retriever side, spotlighting results from the CLEAR study and the promise of the NeVa device — including high reperfusion rates and strong first-pass outcomes.

🚀 Looking ahead, both emphasise the importance of FDA progress, the potential of the NeVa NET to reduce distal emboli, and the need for large prospective studies to shape the future of mechanical thrombectomy.

Prof. Sedar Geyik shares his expectations for 2026, highlighting consistently strong results with NeVa and NeVa NET, including >90% first-pass TICI 2C–3 in early cases and encouraging performance in challenging ICA and M1 occlusions. He emphasises that success comes from both device innovation and operator experience, underpinned by training and high-volume practice.

Dr. Paul Bhogal describes NeVa NET as his current workhorse stent retriever for ICA and M1 cases, noting its role in capturing clot and potentially reducing distal microemboli when used alongside aspiration. Looking ahead, both highlight the importance of device integration, the need for a smaller (3 mm) NeVa option, and the development of optimised aspiration catheters to further improve first-pass success.

🚀 A shared vision for 2026: higher first-pass rates, smarter device combinations, and streamlined thrombectomy workflows.

Reflecting on a landmark year, Diane Demet Tangun highlights 2025 as a breakthrough moment for NeVa and NeVa NET, with multiple publications reinforcing their efficacy, safety, strong first-pass success, and innovative distal emboli protection — even in complex and bailout cases.

Jennifer Geluso points to major global milestones, including FDA clearance of Vesalio’s first aspiration technologies, FDA approval of the ENVAST coronary thrombectomy device, and continued international expansion — all laying strong foundations for what’s next.

Looking ahead, Jessica Koradin shares excitement for 2026, with the future approvals expected in neuro thrombectomy and vasospasm with NeVa 3mm and NeVa VS retrospectively, giving physicians more tools to treat more patients and save more lives worldwide.

🚀 A powerful close to 2025 — and an even more ambitious vision for 2026.

#BRAINConference #StrokeCare #NeuroIntervention #Thrombectomy #Innovation

Many thanks to Vesalio for supporting these videos